News Center
News Type
Rabeprazole sodium enteric-coated tablets were approved, A new member of the Qingfeng digestive family
On August 3, the NMPA approved the marketing of Rabeprazole Sodium Enteric-coated Tablets developed by Shanxiang Pharmaceutical, a subsidiary of Qingfeng Pharmaceutical Group. This is the second proton pump inhibitor approved by Qingfeng Pharmaceutical Group in the field of digestion.
Qingfeng was listed as the "best industrial enterprise in China's pharmaceutical R & D product line"
On August 1, 2021 (the 38th) national pharmaceutical industry information annual conference was grandly opened in Jinan, Shandong Province. The conference officially released the list of the best industrial enterprises in China's pharmaceutical R&D product line in 2021. Qingfeng Pharmaceutical Group was listed on the list with its outstanding R&D and innovation driving force over the years!
Qingfeng won the bid for the fourth batch of national volume based procurement for two products
On February 3, Shanghai Yangguang Pharmaceutical Purchasing Network officially released the bidding results of fourth batch of national volume based procurement. Jiangxi Shanxiang Pharmaceutical Co., Ltd. (a subsidiary of Qingfeng Pharmaceutical Group) stood out for two products and successfully won the bid, namely Bangkaxin® Es omeprazole magnesium enteric-coated Tablets, and Ligesitai® Sorafenib tosylate tablets.
Sorafenib was approved as the first generic in China
The Class 4 chemical generic Sorafenib tosylate tablets (trade name: Ligesitai®) developed by Jiangxi Shanxiang Pharmaceutical Co., Ltd., a subsidiary of Qingfeng Pharmaceutical Group, were approved by the National Medical Products Administration on August 5, 2020. NMPA).
Esomeprazole magnesium enteric-coated tablets was approved as the first generic in China
On July 8, Bangkaxin® (Esomeprazole Magnesium Enteric-coated Tablets) declared by Qingfeng Pharmaceutical Group and Jiangxi Shanxiang Pharmaceutical Co., Ltd. was approved by NMPA.
Qingfeng Pharmaceutical donates 10 million CNY in medicines
On January 29, Qingfeng Pharmaceutical urgently donated 10 million yuan worth of therapeutic drugs to the Jiangxi Charity Federation to fight and prevent pneumonia caused by the new coronavirus.
